WHO categorizes marijuana as 'medical'

The US Drug Enforcement Administration has long held that the non-psychoactive component of marijuana, cannabidiol, is a schedule I drug. That is, a drug that has no accepted medical use and a high potential for abuse. But according to a preliminary report embraced by the World Health Organization this week, the DEA’s long-held stance is tripping.

In a preliminary report last month, the WHO’s Expert Committee on Drug Dependence concluded—and WHO agreed—that clinical and pre-clinical studies of CBD show no evidence of a potential for users to abuse the drug or suffer any harms. Moreover, the experts found plenty of inklings that CBD has medical benefits, particularly for treating epilepsy. In its conclusion, the ECDD declared that the current data “does not justify scheduling of cannabidiol.”

Read more at Ars Technica (Beth Mole)

Publication date :



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


© HortiDaily.com 2018